DV Trading’s Tango Therapeutics TNGX Stock Holding History

DV Trading’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-300,648	Closed	-$6.29M	–	689
2026 Q1	$6.29M	Buy	+300,648	New	+$4.18M	0.15%	62

Other funds holding TNGX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

DV Trading's TNGX Position: Q2 2026 in Review

DV Trading sold out of Tango Therapeutics (TNGX) in Q2 2026, closing a stake of 300,648 shares — an estimated $6.29M sold.

DV Trading first reported a position in TNGX in Q1 2026 and held it in 1 quarter. The position peaked at $6.29M in Q1 2026. 246 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

DV Trading reported no remaining Tango Therapeutics position as of Q2 2026 after selling out during the quarter.
DV Trading sold 300,648 Tango Therapeutics shares in Q2 2026, an estimated $6.29M.
DV Trading first reported a position in Tango Therapeutics in Q1 2026 and held it in 1 quarter.
DV Trading's Tango Therapeutics position peaked at $6.29M in Q1 2026.
246 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on DV Trading's 13F filing for Q2 2026, filed 14 Aug 2026.